Copy
View this email in your browser

Cancer Evidence Update

September 2016

Talimogene laherparepvec for treating unresectable metastatic melanoma .

Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer

Degarelix for treating advanced hormone-dependent prostate cancer

Skin cancer

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
We really appreciate your comments and suggestions, so please do send them to your Cancer Clinical Librarian, Keith Nockels via email.

You can also sign up for our Breast Cancer or Haematology update.
New and Updated Cochrane Systematic Reviews

Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers
Authors' conclusions: We found no evidence that undertaking therapeutic exercises before, during and/or immediately after HNC treatment leads to improvement in oral swallowing. This absence of evidence may be due to the small participant numbers in trials, resulting in insufficient power to detect any difference. Data from the identified trials could not be combined due to differences in the choice of primary outcomes and in the measurement tools used to assess them, and the differing baseline and endpoints across studies.

Designing and implementing studies with stronger methodological rigour is essential. There needs to be agreement about the key primary outcomes, the choice of validated assessment tools to measure them and the time points at which those measurements are made.

Febrile neutropenia
  • low bacteria diets may not reduce infection in patients with cancer receiving chemotherapy (Cochrane Database Syst Rev 2016 Apr 24).
Prostate cancer
  • NICE guidance on abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (National Guideline Clearinghouse 2016 Sep 12) 
  • 11.8% prevalence of germline mutations in DNA repair genes in men with metastatic prostate cancer, regardless of family history or age at diagnosis (N Engl J Med 2016 Aug 4) 
Macmillan Cancer Support
Macmillan Cancer Support responds to the latest cancer waiting times figures.
Find the waiting time statistics here 

Macmillan Cancer Support responds to new data on post- chemotherapy deaths.
Other High Quality Research

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer


Biologic and Clinical Perspectives on Thyroid Cancer.

Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.

Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis.

Comparison study of distinguishing cancerous and normal prostate epithelial cells by confocal and polarization diffraction imaging.

Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives.

The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.

Glyco-genes change expression in cancer through aberrant methylation.

Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.



**Links will not work from UHL computers using older versions of Internet Explorer, please use an alternative browser**
To access full text you may have to log in to your NHS Athens account (click here to register for free). If full text is not available then please email us to request a copy.
Leicester publications

Cancer Drugs Fund requires further reform.

Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.


**Links will not work from UHL computers using older versions of Internet Explorer, please use an alternative browser**
Other Sources

All Party Parliamentary Group on Cancer (APPGC)
The  APPGC and Macmillian recently examined  the progress made since the publication of Achieving World-Class Cancer Outcomes: A Strategy for England 2015–2020 (the England Cancer Strategy).You can read the APPGC's findings and recommendations from the recent inquiry in the report 'Progress into the England Cancer Strategy: One year on'.

 
 American Association for Cancer Research
The AACR 2016  Cancer Progress Report seeks to capture the breadth and depth of advances that have been discovered  in the cancer field.


BBC News
Brain radiotherapy 'no benefit' for lung cancer spread. @ http://www.bbc.co.uk/news/health-37255399. Link to study found on the website.

Cancer gene tests 'reveal family link" @ http://www.bbc.co.uk/news/health-36977400. Link to report found in a  Lancet article.

Cervical screening 'can save more lives' @ http://www.bbc.co.uk/news/health-37375895Additional link to report found in a  BJC article

The Guardian
New drug 'wakes up' immune system to fight one of deadliest cancers

Cancer patients not given painkillers soon enough, study finds

GOV.UK
New findings on post-chemotherapy deaths using world-first PHE cancer data
News story: New findings on post-chemotherapy deaths using world-first PHE cancer data
 
The first major report using world-first systemic anticancer treatment (SACT) data has been published by Lancet Oncology today (30 August 2016).
Research and analysis: Chemotherapy for breast and lung cancer: 30-day mortality

Below is the updated Indication on the EAMS scientific opinion given to pembrolizumab for metastatic non-small cell lung cancer (NSCLC), including the public assessment report.
Decision: Early access to medicines scheme (EAMS) scientific opinion: pembrolizumab for non-small cell lung cancer

Public Health England
Trust level 30 day mortality after systemic anticancer treatment for breast and lung cancer in England

This cancer report is co-authored by PHE’s National Cancer Registration and Analysis Service and Cancer Research UK and is the first major report using world-first systemic anticancer treatment (SACT) data.  This is a companion report to the first reference under Other High Quality Research, above.
NHS Behind the Headlines -  media stories explained

Women dying needlessly due to not attending cervical screening  

Invasive early prostate cancer treatments not always needed  


Radiotherapy 'provides no benefit for secondary brain tumours'  

Gene scanning 'could improve screening for oesophageal cancer'

Women's cancer risk may increase the longer they're obese  

UK heart disease and stroke death rates now lower than cancer
Table of Contents
Annals of Oncology
Anti-Cancer Drugs
British Journal of Cancer
Cancer
Cancer Imaging
Cancer Nursing
Cancer Causes & Control
Clinical oncology
JAMA Oncology
Lancet Oncology
Radiotherapy and Oncology
Our mailing address is: keith.nockels@uhl-tr.nhs.uk
 
Copyright © 2016 UHL Clinical Librarian Service, All rights reserved.
Share
Tweet
Forward






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UHL Clinical Librarian Service · Odames Library Level 1, Victoria Building, · Royal Infirmary, Infirmary Square · Leicester, LE1 5WW · United Kingdom

Email Marketing Powered by Mailchimp